Patients with HR-positive, HER2-negative high-risk early breast cancer tended to experience improved invasive disease and distant relapse-free survival after adding Verzenio to endocrine therapy.
In the heat of the CDK4/6 market showdown, Eli Lilly has notched an overall survival win to back Verzenio’s case against Novartis’ rival offering. Lilly’s Verzenio has proven its ability to prolong ...
Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to be presented as a late-breaking oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback